Management of diarrhea-associated hemolytic uremic syndrome in children

Review Article


Most cases of diarrhea-associated hemolytic uremic syndrome (D+HUS) are caused by Shiga toxin-producing bacteria. Shiga toxin-producing Escherichia coli (STEC) O157:H7 has the strongest association worldwide with HUS. A massive outbreak of E. coli O157:H7 infections in Sakai, Osaka, Japan, in 1996 raised public and medical awareness of STEC. However, most cases are sporadic or occur in small clusters. Indeed, more than 100 sporadic or small cluster cases of D+HUS occur every year in Japan. The use of antibiotics in patients with definite or possible enteric STEC infections is controversial; however, there has been no randomized controlled trial to date showing the effectiveness of antibiotics for the prevention of the development of HUS. Thus, most investigators in western countries believe that antibiotics should not be administered to patients with such infections, and the management of HUS remains supportive. There are no specific therapies to ameliorate the course of the disease, and vascular injury leading to HUS is likely to be well under way by the time infected patients seek medical attention for diarrhea. The best way to prevent HUS is to prevent primary infection by Shiga toxin-producing bacteria.


Diarrhea-associated hemolytic uremic syndrome Large-scale national survey of HUS in Japan Prevention Antibiotics Management 


  1. 1.
    Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983;1:619–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Yoshioka K, Yagi K, Moriguchi N. Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection: experience of an outbreak in Sakai City, 1996. Pediatr Int. 1999;41:223–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Fukushima H, Hashizume T, Morita Y, Tanaka J, Azuma K, Mizumoto Y, Kaneno M, Matsuura M, Konma K, Kitani T. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int. 1999;41:213–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Bitzan M, Bickford BB, Foster GH. Verotoxin (Shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. J Am Soc Nephrol. 2004;15:2334–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Kamioka I, Yoshiya K, Satomura K, Kaito H, Fujita T, Iijima K, Nakanishi K, Yoshikawa N, Nozu K, Matsuo M. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int. 2007 (in press).Google Scholar
  6. 6.
    Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998;352:1207–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 1997;100:E12.PubMedCrossRefGoogle Scholar
  8. 8.
    Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2001;33:923–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998;17:761–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis. 2000;6:458–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA. 2002;288:996–1001.PubMedCrossRefGoogle Scholar
  13. 13.
    Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol. 1999;52:357–62.PubMedGoogle Scholar
  14. 14.
    Wong CS, Brandt JR. Risk of hemolytic uremic syndrome from antibiotic treatment of Escherichia coli O157:H7 colitis. JAMA. 2002;288:3111.PubMedCrossRefGoogle Scholar
  15. 15.
    Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073–86.PubMedGoogle Scholar
  16. 16.
    Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005;115:e673–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am. 2001;30:735–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA. 2003;291:1337–44.CrossRefGoogle Scholar
  19. 19.
    Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol. 1998;12:101–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Diekmann L. Treatment of the hemolytic-uremic syndrome with streptokinase and heparin (author’s transl). Klin Padiatr. 1980;192:430–5.PubMedCrossRefGoogle Scholar
  21. 21.
    O’Regan S, Chesney RW, Mongeau JG, Robitaille P. Aspirin and dipyridamole therapy in the hemolytic-uremic syndrome. J Pediatr. 1980;97:473–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Gianviti A, Perna A, Caringella A, et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis. 1993;22:264–6.PubMedGoogle Scholar
  23. 23.
    Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma: a multicentre randomized controlled trial. Pediatr Nephrol. 1988;2:279–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988;112:284–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Ogborn MR, Crocker JF, Barnard DR. Plasma therapy for severe hemolytic-uremic syndrome in children in Atlantic Canada. CMAJ. 1990;143:1323–6.PubMedGoogle Scholar
  26. 26.
    Hughes DA, Beattie TJ, Murphy AV. Haemolytic uraemic syndrome: 17 years experience in a Scottish paediatric renal unit. Scott Med J. 1991;36:9–12.PubMedGoogle Scholar
  27. 27.
    Taylor CM, White RH, Winterborn MH, Rowe B. Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands. Br Med J (Clin Res Ed). 1986;292:1513–6.Google Scholar
  28. 28.
    Bale JF Jr, Brasher C, Siegler RL. CNS manifestations of the hemolytic-uremic syndrome: relationship to metabolic alterations and prognosis. Am J Dis Child. 1980;134:869–72.PubMedGoogle Scholar
  29. 29.
    Brandt JR, Fouser LS, Watkins SL, et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr. 1994;125:519–26.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2008

Authors and Affiliations

  1. 1.Department of NephrologyNational Children’s Medical Center, National Center for Child Health and DevelopmentTokyoJapan
  2. 2.Department of PediatricsKobe University Graduate School of MedicineKobeJapan

Personalised recommendations